Phim Sex Filme Porno PORNO GRÁTIS Filme Porno Phim Sex “Penny Stocks that Perform” News today is: ADVS, BIEL, BMRN, CYNO | Pharmacy News EU

Article written

  • on 30.06.2009
  • at 10:00 PM
  • by admin

“Penny Stocks that Perform” News today is: ADVS, BIEL, BMRN, CYNO

Jun30

Pennyperformers.com "Penny Stocks that Perform" picks are: Advent Software, Inc. (NASDAQ: ADVS), BioElectronics Corp. (PINKSHEETS: BIEL), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Cynosure, Inc. (NASDAQ: CYNO)
Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com
Jul 1, 2009 Advent Software, Inc. (NASDAQ: ADVS), a leading provider of software and services for the global investment management industry, today announced that it has been recognized by Waters magazine as having the ‘Best Portfolio Management System.’
"It is an honor to be recognized by Waters magazine and our customers as the best portfolio management provider," said Stephanie DiMarco, Founder and Chief Executive Officer of Advent. "Client satisfaction is our top priority and this award underscores our ongoing commitment to enhancing the breadth and depth of our solutions. More than 4,500 investment management firms worldwide depend on Advent solutions for mission-critical functions, and we remain dedicated to meeting and exceeding our clients’ expectations by addressing their specific business needs and helping to give them a competitive advantage."
Advent offers three distinct portfolio management solutions to meet the diverse needs of the marketplace:
Geneva(R) is Advent’s global portfolio management and fund accounting solution designed to meet the real-time needs of firms with complex, international accounting requirements and/or wide instrument coverage needs, including alternative investments such as exchange-traded and over- the-counter derivatives.
Advent Portfolio Exchange(R) (APX) is Advent’s end-to-end portfolio management solution that integrates the front-office functions of prospecting, marketing, and customer relationship management with the back- office operations of portfolio accounting and reporting.
Axys(R) is Advent’s turnkey portfolio management and reporting system for small to mid-size investment management organizations. It provides investment professionals with broad portfolio accounting functionality on a variety of investment instruments, including equities, fixed income, mutual funds and cash.
The Waters Rankings are the annual readers’ choice awards of Waters magazine, which recognize the combined leadership of technological capabilities and human expertise in each category. Qualified voters included buy- and sell-side firms as well as exchanges and brokerages.
These awards are the latest in a series of recent industry recognition for Advent that includes: Best Technology Provider, HFMWeek; Global Securities Services Technology Vendor of the Year, ICFA; Best Buy-Side Fund Accounting System and Best Buy-Side Client Reporting System, Buy-Side Technology; and FinTech Top 100, American Banker and Financial Insights.
About Advent
Advent Software, Inc., a global firm, has provided trusted solutions to the world’s financial professionals since 1983. Today firms in 60 countries rely on Advent technology to run their mission-critical operations. Advent’s quality software, data, services and tools enable financial professionals to improve service and communication to their clients, allowing them to grow their business while controlling costs. Advent is the only financial services software company to be awarded the Service Capability and Performance certification for being a world-class support and services organization.
The Advent logo, Advent Software, Advent Portfolio Exchange, Axys and Geneva are registered trademarks of Advent Software, Inc. All other company names or marks mentioned herein are those of their respective owners.
Jul 1, 2009 BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today released the following statements from the management team and leading physicians regarding the recent FDA panel recommendation to lower the maximum daily dosage of acetaminophen and to restrict the sale of large acetaminophen dosages such as those contained in Extra Strength Tylenol(R).
"We are developing significant momentum around the world in the use of both ActiPatch(R) Therapy and the Allay(TM) Menstrual Pain Relief Patch as a safe and effective alternative to acetaminophen," said Andrew Whelan, CEO BioElectronics Corp. "Pulsed ElectroMagnetic Field (PEMF) Therapy has been proven safe and effective in hundreds of peer-reviewed scientific studies and is a strong alternative therapy for many types of musculoskeletal complaints and surgical recovery. We welcome the FDA panel’s findings that acetaminophen usage is potentially dangerous and should be restricted," Whelan said. "We look forward delivering our proven safe and effective drug-free pain relief and healing technology to the American market as our clinical studies move toward conclusion." Physicians experienced with the BioElectronics product line made the following comments.
Barry Eppley, M.D., D.M.D., Indianapolis Plastic Surgeon
"The use of BioElectronics’ RecoveryRx(TM) allows me to reduce my patients’ use of post-operative medications including Tylenol(R). My clinical studies have also shown BioElectronic’s Allay technology to be a very safe and highly effective treatment alternative for dysmenorrhea (period pain), one of the most common types of pain experienced by most women. Congratulations to BioElectronics on the development of these drug-free, pain relieving technologies."
David Genocov, M.D. Specialist in Craniomaxillofacial Surgery
"As a physician I am always concerned about the overuse of narcotics and NSAIDS. Whenever possible our role is to reduce the use of these medications. To this end I currently use PEMF therapy in the form of the ActiPatch as an adjunctive therapy in the post-operative environment. The use of these devices has allowed me to significantly reduce the use of narcotics and NSAIDs to control pain among my patient population."
Sheena Kong, M.D. Internal Medicine
"More and more of my patients are seeking drug-free solutions to pain relief. Use of Tylenol and other OTC pain medications is problematic for many types of patients and NSAIDs are often not a safe option. In my practice I have found both the ActiPatch and Allay Period Relief Patch products to be safe and effective alternatives. I believe the panel’s recommendations are sound as many patients are unaware of the potential dangers of these drugs."
About BioElectronics Corporation
BioElectronics Corporation is the maker of patented ActiPatch(R) Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com) and Allay(TM) family of inexpensive, disposable drug-free anti-inflammatory devices. These devices utilize embedded battery operated microchips to deliver weeks of home therapy for only about a dollar a day. The unique delivery system, using patented technology, provides a cost effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch Therapy is approved by Health Canada for the relief of pain and musculoskeletal complaints. The US government food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a Class II pulsed electromagnetic medical device as have numerous other international agencies.
Jul 1, 2009 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 30, at 5:00 p.m. ET (23:00 CET) to discuss second quarter 2009 financial results.
U.S. / Canada Dial-in Number: 866.272.9941 International Dial-in Number: 617.213.8895 Participant Code: 45596036 Replay Dial-in Number: 888.286.8010 Replay International Dial-in Number: 617.801.6888 Replay Code: 74141589
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of MPS IVA.
Jul 1, 2009 Cynosure, Inc. (NASDAQ: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced that it has signed a multi-year, funded cooperative agreement with Unilever Ltd. to develop and commercialize light-based devices targeting the home use personal care market. Financial terms of the agreement were not disclosed.
"One of our long-term corporate objectives has been to enter the emerging home use market, and Unilever represents an ideal partner for us," said President and Chief Executive Officer Michael Davin. "We view this agreement as a first step in forming a meaningful long-term strategic relationship with Unilever and an attractive business opportunity for Cynosure. Unilever is a recognized leader in skin care products, including a broad array of established consumer brands such as Dove, Pond’s and Vaseline. Its world-class distribution, marketing and branding capabilities for home skin care products are second to none. With its global footprint, Unilever has the scale to successfully launch and distribute light-based products into the consumer market."
"Together with Unilever, we intend to target multiple benefit areas within the home use segment," Davin said. "The initial focus of this funded development agreement will be on the skin rejuvenation component of the marketplace, which includes wrinkles, lines and texture. We hope our current light-based technology for skin rejuvenation will translate well into the over-the-counter device market."
Genevieve Berger, Unilever’s Chief Research and Development Officer, commented, "We believe the emerging consumer market for light-based devices is a promising long-term opportunity for Unilever. We selected Cynosure as our development partner because of the company’s ability to develop and bring leading-edge technology into the marketplace and its demonstrated success as an innovator in the physician based aesthetic market. Cynosure has proven that it can develop products that not only deliver outstanding clinical results but also emphasize safety, which is a critical element for the consumer marketplace. We look forward to working with the Cynosure team in the years ahead."
About Unilever
Unilever’s mission is to add vitality to life. They meet everyday needs for nutrition, hygiene and personal care with brands that help people feel good, look good and get more out of life. Unilever is one of the world’s leading suppliers of fast moving consumer goods with strong local roots in more than 100 countries across the globe. Its portfolio includes some of the world’s best known and most loved brands including thirteen euro 1 billion brands and global leadership in many categories in which the company operates. The portfolio features brand icons such as Knorr, Wall’s, Flora, Dove, Lynx, Persil, Marmite and Pot Noodle. Unilever has around 174,000 employees in approaching 100 countries and generated annual sales of euro 40 billion in 2008.
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure’s products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.
About PennyPerformers.com
PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.
Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the "join now" button.
Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market.
Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm
For More Information Regarding Penny Performers, Contact Jason A. Hilton at: Rochester, Ny 14609 Office: (866)704-0122 Email: Jason@Newmediaadvisorsllc.com
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS

subscribe to comments RSS

Comments are closed